Aspira Women's Health Inc.

Aspira sells primarily into the U.S. healthcare system, where its customers are physicians, healthcare systems, and large physician practices that order tests for patients with suspected gynecologic disease. The end users are women being evaluated for ovarian cancer risk, endometriosis, benign pelvic masses, or other pelvic conditions where traditional diagnostics may be less specific. Revenue is also influenced by third-party payers, Medicare, Medicaid, and patient-pay arrangements because reimbursement determines whether tests are adopted and how much revenue is ultimately realized. The company also depends on commercial and distribution partners that can broaden access to its tests and support future market expansion.

Aspira’s strategy is to move beyond ovarian cancer and position its biomarker platform as a broader diagnostic tool for women’s gynecologic disease. Management is trying to grow utilization of OvaSuite products, secure payer coverage, and expand physician adoption through both direct commercialization and decentralized distribution agreements. The company is also investing in Aspira Labs’ molecular capabilities so it can support current testing and future product launches with more control over operations. Longer term, partnerships, licensing, and out-licensing are intended to extend the platform beyond the U.S. without requiring a large direct international sales buildout.